Kura Oncology, Inc.
KURAKura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company's pipeline primarily includes small-molecule drugs designed to selectively inhibit specific proteins involved in cancer growth and progression. Based in San Diego, California, Kura aims to address unmet medical needs in oncology with precision medicines.
Company News
Kyowa Kirin and Kura Oncology announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial for ziftomenib, an oral menin inhibitor for treating relapsed or refractory NPM1-mutated acute myeloid leukemia. Ziftomenib was previously approved by the FDA in November 2025 under the brand name KOMZIFTI. Following trial ...
Kura Oncology announced preliminary data from the FIT-001 clinical trial showing that darlifarnib combined with cabozantinib demonstrated a 44% objective response rate and 94% disease control rate in cabozantinib-pretreated clear cell renal cell carcinoma patients. The combination showed tumor shrinkage in 75% of patients with durable treatment d...
Kura Oncology granted nonstatutory stock options to purchase 153,750 shares to six new employees on April 1, 2026, with an exercise price of $8.34 per share. The options vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Kura Oncology and Kyowa Kirin announced FDA approval of KOMZIFTI, a once-daily oral menin inhibitor for relapsed/refractory NPM1-mutated AML, which has been added to NCCN Guidelines as a recommended treatment option.
